Studies on the supramolecular complex of a guanosine with beta-cyclodextrin and evaluation of its anti-proliferative activity

The behavior of the inclusion behavior of guanosine (GU) with beta-cyclodextrin (β-CD) in the liquid, solid and virtual state were investigated. The absorption and fluorescence spectral were used to determine the inclusion behavior in liquid state. FT-IR, NMR, TGA, DSC, PXRD and FESEM techniques we...

Full description

Main Authors: Prabu, S., Samad, N.A., Ahmad, N.A., Jumbri, K., Raoov, M., Rahim, N.Y., Samikannu, K., Mohamad, S.
Format: Article
Institution: Universiti Teknologi Petronas
Record Id / ISBN-0: utp-eprints.29784 /
Published: Elsevier Ltd 2020
Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090364556&doi=10.1016%2fj.carres.2020.108138&partnerID=40&md5=fd9cf4353a742d22bed70886f9c4742d
http://eprints.utp.edu.my/29784/
Tags: Add Tag
No Tags, Be the first to tag this record!
Summary: The behavior of the inclusion behavior of guanosine (GU) with beta-cyclodextrin (β-CD) in the liquid, solid and virtual state were investigated. The absorption and fluorescence spectral were used to determine the inclusion behavior in liquid state. FT-IR, NMR, TGA, DSC, PXRD and FESEM techniques were used to investigate the inclusion behavior in solid-state, meanwhile the virtual state studies are done by molecular docking. The solid inclusion complex (GU: β-CD) was prepared by using the co-precipitation method. The binding constant (K) of (GU: β-CD) was calculated by using Benesi-Hildebrand. Besides that, the 1:1 stoichiometric ratio of inclusion complex was confirmed by using the Benesi-Hildebrand plot and Job's plot of continuous variation method. The most preferable model of GU: β-CD that suggested via molecular docking studies was in good agreement with experimental results. The inclusion complex of GU: β-CD exerted its toxicity effects towards HepG2 cell lines based on the reduced number of cell viability and lowest IC50 value compared to the GU and β-CD viability. © 2020 Elsevier Ltd